Constantine Tam: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia
Treatment with zanubrutinib resulted in a higher combined complete response and very good partial response rate than therapy with ibrutinib in patients with Waldenström...
John Kuruvilla: Pembrolizumab in Relapsed/Refractory Classic Hodgkin Lymphoma
Treatment with pembrolizumab prolonged progression-free survival more than brentuximab vedotin, including in patients ineligible for transplant. Dr. Kuruvilla discusses results from the phase III...
Meletios Dimopoulos: Weekly SVd Improved PFS in Relapsed/Refractory Myeloma
Once weekly combination treatment with selinexor, bortezomib, and dexamethasone led to an approximately 4-month improvement in progression-free survival compared with bortezomib plus dexamethasone. Meletios...
Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed Myeloma
Initial treatment with carfilzomib, lenalidomide, and dexamethasone was not associated with greater improvements in progression-free survival compared with bortezomib, lenalidomide, and dexamethasone. Shaji Kumar,...
Ajay Nooka: Belantamab Mafodotin in Relapsed/Refractory Myeloma
Ajay K. Nooka, MD, shares safety and efficacy data from the phase II DREAMM-6 trial.
Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL
Constantine S. Tam, MBBS, MD, discusses findings from the phase III SEQUOIA trial, in which 92% of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma...
Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline CLL
Nearly half of patients treated with acalabrutinib plus venetoclax and obinutuzumab achieved a complete response with undetectable minimal residual disease. Benjamin L. Lampson, MD,...
David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML
Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman,...
Jacqueline Garcia: Evaluating Navitoclax for Myelofibrosis
Jacqueline S. Garcia, MD, shares results from a phase II study of navitoclax, an investigational disease-modifying therapy for the treatment of myelofibrosis, which appears...
Abby Statler: Are Clinical Trials Exclusion Criteria for AML Too Strict?
Abby Statler, PhD, MPH, discusses findings from an analysis of common clinical trial exclusion criteria and outcomes in clinical trials, which suggest that eligibility...
Current Issue
October 2020 Volume 6, Issue 12
This issue examines racism in hematology, discusses the FDA's newly loosened blood donation restrictions, and more.